XIAOQING LIU: Open Payments
NPI 1841234002 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,155 in 49 payments from 15 companies in 2025. Trend: 2023 $2,029 · 2024 $2,170 · 2025 $1,155
Food & beverage: $1,136Education: $19
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 5 | $218 |
| ABBVIE INC. | 13 | $186 |
| Janssen Pharmaceuticals, Inc | 6 | $180 |
| Otsuka America Pharmaceutical, Inc. | 4 | $96 |
| E.R. Squibb & Sons, L.L.C. | 3 | $78 |
| Lundbeck LLC | 2 | $59 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
| Noven Therapeutics, LLC | 3 | $56 |
| Neurocrine BioSciences, Inc. | 2 | $55 |
| Bausch Health US, LLC | 2 | $44 |
Products named: Auvelity, VRAYLAR, REXULTI, COBENFY, INVEGA, INVEGA SUSTENNA, CAPLYTA, Xelstrym.
Industry payments across TX — which companies pay providers there.
